Evidence map›Paper›PMID 31745646›Full record

ReviewEuropean archives of psychiatry and clinical neuroscience2021

Esketamine: a glimmer of hope in treatment-resistant depression.

Upinder Kaur, Bhairav Kumar Pathak, Amit Singh, Sankha Shubhra Chakrabarti

2 registry-linked trialsAbstract readReview
PubMed Publisher
In one paragraph

Review in European archives of psychiatry and clinical neuroscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05718024 phase4completednot on this mapstarted 2023, after this paper: background citation

Impact of Night-time Dexmedetomidine-esketamine Infusion on Sleep Quality of Patients With Mechanical Ventilation or High-flow Nasal Cannula Oxygen Therapy in ICU: a Randomized Controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2023 to 2025Enrolled174ConditionsIntensive Care Unit, Mechanical Ventilation, Dexmedetomidine, EsketamineArmsDexmedetomidine-esketamine, Routine sedation and analgesia
NCT06003218 nacompletednot on this mapstarted 2023, after this paper: background citation

Dexmedetomidine-esketamine Combined With Oxycodone for Ultrasound-guided Percutaneous Radiofrequency Ablation in Patients With Liver Cancer: a Randomized Controlled Study

TypeinterventionalSponsorPeking University First HospitalRan2023 to 2024Enrolled88ConditionsLiver Cancer, Radiofrequency Ablation, Esketamine, DexmedetomidineArmsDexmedetomidine-esketamine combination, Remifentanil, Oxycodone
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Upinder KaurDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Bhairav Kumar PathakDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Amit SinghDepartment of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Sankha Shubhra ChakrabartiDepartment of Geriatric Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India. sankha.geriatrics@gmail.com.ORCID http://orcid.org/0000-0001-7737-0016

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The motive of this article is to review the pharmacological and clinical aspects of esketamine (ESK), an NMDA-receptor antagonist approved recently by the FDA for treatment-resistant depression (TRD). PubMed/Medline database was searched using keywords 'esketamine' and 'depression', 'S-ketamine' and 'depression', and 'NMDA antagonist' and 'depression'. Individual trials were searched from ClinicalTrials.gov. We included English-language articles evaluating pharmacokinetics and pharmacodynamics of intranasal (IN) esketamine, along with clinical trial data related to its efficacy and safety in patients diagnosed with TRD. Compared to placebo, IN esketamine causes significant and rapid improvement in depression. Dizziness, vertigo, headache, increase in blood pressure are some of its common adverse effects. With the growing number of patients of TRD, additional effective and safe treatment is the need of the hour. Esketamine appears to be an effective therapy when combined with oral antidepressants in patients with TRD. It is of special value due to the rapid onset of its action. Long-term clinical studies are, however, needed to ascertain its safety profile.

Indexed as

Clinical Trials, Phase III as TopicAntidepressive AgentsDepressive Disorder, Treatment-ResistantDrug Therapy, CombinationExcitatory Amino Acid AntagonistsHumansKetamineReceptors, N-Methyl-D-AspartateAntidepressive AgentsEsketamineExcitatory Amino Acid AntagonistsKetamineReceptors, N-Methyl-D-AspartateIntranasalNMDARapid onsetTreatment-resistant depression

Identifiers

PMID31745646

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.